Christophe Weber, CEO of Takeda Pharma, discusses the group's plans to invest $30 billion into its U.S. operations over the ...

Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...

Earnings Call Insights: Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Christophe Weber, CEO, announced his ...

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

TOKYO -- Japanese drugmaker Takeda Pharmaceuticals will invest $30 billion in the U.S. over the next five years, CEO ...

Q4 2024 Earnings Call Transcript May 9, 2025 Christopher O’Reilly: Thank you very much for taking time out of their busy ...

Takeda Pharmaceuticals, Japan's largest drugmaker, has undergone a sweeping transformation under CEO Christophe Weber, emerging as one of the world's leading pharmaceutical companies. Crowds in St ...

Takeda has been restructured under new CEO Christophe Weber, who took over in 2014 and has focused the company on cancer and specialist gastrointestinal drugs, and early stage central nervous ...

Takeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and ...